{"name":"Theradex","slug":"theradex","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BBR 3464","genericName":"BBR 3464","slug":"bbr-3464","indication":"Relapsing multiple sclerosis","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"DHA-paclitaxel","genericName":"DHA-paclitaxel","slug":"dha-paclitaxel","indication":"Breast cancer","status":"phase_2"}]}],"pipeline":[{"name":"BBR 3464","genericName":"BBR 3464","slug":"bbr-3464","phase":"phase_2","mechanism":"BBR 3464 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Relapsing multiple sclerosis"],"catalyst":""},{"name":"DHA-paclitaxel","genericName":"DHA-paclitaxel","slug":"dha-paclitaxel","phase":"phase_2","mechanism":"Paclitaxel binds to tubulin, inhibiting microtubule formation and cell division.","indications":["Breast cancer","Ovarian cancer","Lung cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPU2ZmZHRfVjZoUzJuUG1JSjBuWndNRXF2bHdhV1BhcFpfMWxXdlJJenRPU2FCUlo2OUlsZnhxUUlSR2FyMzNmSXFnZU15LVYyMDBYck5EeGZyMXI1Z3ViNTRWcHZyaUI3bTVwVFVOSkJ3eW56RE9VYXg4YU9VWEpRdnF5YXZuQlFuZlozeUhlWTFHZVA4Qm9NbQ?oc=5","date":"2017-04-13","type":"trial","source":"Fierce Biotech","summary":"Moleculin hires Theradex to help run its clinical AML study - Fierce Biotech","headline":"Moleculin hires Theradex to help run its clinical AML study","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}